145039-51-6

Basic information

• Product Name: 2-Propen-1-one,3-(2-hydroxy-3,4,6-trimethoxyphenyl)-1-phenyl-, (2E)-
• Synonyms: 2-Propen-1-one,3-(2-hydroxy-3,4,6-trimethoxyphenyl)-1-phenyl-, (E)-; (E)-2-Hydroxy-3,4,6-trimethoxychalcone;Tepanone
• CAS NO: 145039-51-6
• Molecular Formula: C18H18 O5
• Molecular Weight: 314.338
• Mol File: 145039-51-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-Propen-1-one,3-(2-hydroxy-3,4,6-trimethoxyphenyl)-1-phenyl-, (2E)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Propen-1-one,3-(2-hydroxy-3,4,6-trimethoxyphenyl)-1-phenyl-, (2E)-(145039-51-6)
• EPA Substance Registry System: 2-Propen-1-one,3-(2-hydroxy-3,4,6-trimethoxyphenyl)-1-phenyl-, (2E)-(145039-51-6)

Safety Data

• Hazardous Substances Data: 145039-51-6(Hazardous Substances Data)

Upstream product

• 65162-31-4 2-hydroxy-3,4,6-trimethoxybenzaldehyde 
• 20913-05-7 (Benzoylmethylene)triphenylphosphorane 
• 23050-38-6 5,7,8-trimethoxy-2-phenyl-chromen-4-one 

Downstream Products

• 145039-91-4 trans-Methyltepanone 

Relevant articles and documents

Oxidative Dimerization of 1 H-Benzo[f]chromenes: Synthesis of Benzannulated Analogues of Spirobiflavonoids Welwitschins e and F

A new oxidative transformation of 1 H -benzo[ f ]chromenes into spirodimers under the action of selenium dioxide was discovered, leading to spirodimers, which are dibenzannulated analogues of naturally occurring welwitschins E and F. In the reaction, both MnO 2and I 2O 5can also be used as an oxidant. The protocol has advantages of mild reaction conditions and simple operation. At the same time, oxidation of 1 H -benzo[ f ]chromenes with (diacetoxyiodo)benzene is accompanied by the formation of 3,3′-bibenzo[ f ]chromene as a dimer of a different structure. It was also found that 4 H -chromenes under the action of various oxidants are cleaved to give chalcone.

Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones

The invention relates to the use of 1,3-bis-aromatic-prop-2-en-1-ones (chalcones), 1,3-bis-aromatic-propan-1-ones (dihydrochalcones), and 1,3-bis-aromatic-prop-2-yn-1-ones for the preparation of pharmaceutical compositions for the treatment or prophylaxis of a number of serious diseases including i) conditions relating to harmful effects of inflammatory cytokines, ii) conditions involving infection by Helicobacter species, iii) conditions involving infection by viruses, iv) neoplastic disorders, and v) conditions caused by microorganisms or parasites. The invention also relates to novel chalcones and dihydrochalcones (especially alkoxy substituted variants) having advantageous substitution patterns with respect to their effect as drug substances, and to methods of preparing them, as well as to pharmaceutical compositions comprising the novel chalcones. Moreover, the present invention relates to a method for the isolation of Leishmania fumarate reductase, QSAR methodologies for selecting potent compounds for the above-mentioned purposes.